Nuvectis Pharma, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The unaudited statements are prepared under U.S. GAAP. Nuvectis is a clinical-stage biopharmaceutical company developing precision oncology medicines; it has generated no revenue to date.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $0 | $0; no product revenue to date |
| Research and development expense | $2.660 million | $2.367 million; up $293,000 |
| General and administrative expense | $1.736 million | $1.734 million; up $2,000 |
| Operating loss | $4.396 million | $4.101 million |
| Finance income | $225,000 | $52,000 |
| Net loss / loss per share | $4.171 million / $0.25 | $4.049 million / $0.27 |
| Operating cash flow | $(4.358) million | $(4.777) million |
| Cash and cash equivalents | $19.464 million at March 31 | $19.126 million at December 31, 2023 |
| Total assets / liabilities | $19.714 million / $5.692 million | $19.185 million / $6.984 million at December 31, 2023 |
Net cash from financing was $4.696 million, primarily from the ATM offering; investing cash flow was zero. No debt is reported. With no revenue, profit margins are not meaningful. Cash rose $338,000 during the quarter, reflecting ATM proceeds that exceeded operating cash use.
Business, progress, and period-over-period changes
Nuvectis is advancing NXP800, an oral integrated stress response activator, and NXP900, a SRC-family kinase inhibitor. NXP800’s Phase 1b expansion is evaluating patients with platinum-resistant, ARID1a-mutated ovarian carcinoma; the company also described a planned investigator-sponsored cholangiocarcinoma study with Mayo Clinic. NXP900’s Phase 1a dose-escalation study began in September 2023.
Research and development expense increased 12% year over year, mainly due to higher employee compensation and benefits, clinical-trial costs, and manufacturing costs. General and administrative expense was essentially unchanged. Net loss increased by $122,000, while loss per share improved from $0.27 to $0.25, alongside a higher weighted-average share count. Operating cash use declined by $419,000 year over year.
Liquidity, financing, outlook, and risks
- Management believes March 31 cash will fund planned operations for at least 12 months from the financial-statement issuance date. The company expects to need additional capital to complete clinical development and warns financing may not be available on acceptable terms.
- During Q1, the company sold 502,647 shares through its ATM at an average $9.31 per share, receiving about $4.7 million net. Approximately $29.9 million remained available under the ATM at quarter-end. Common shares outstanding increased to 18,356,060 from 17,418,886 at December 31, 2023.
- Management expects R&D spending to increase substantially as preclinical and clinical programs advance; it also anticipates higher G&A costs. No specific financial or clinical guidance was provided.
- License obligations are substantially milestone- and sales-contingent and were not accrued. Potential NXP800 obligations include up to $22.0 million in pre-approval milestones and up to $178 million in additional regulatory and commercial milestones, plus tiered royalties. NXP900 obligations include up to $45.0 million in pre-approval milestones and up to $279.6 million in additional milestones, plus tiered royalties and a fundraising payment obligation. The company also reports future research-support commitments.
- Key risks include clinical and regulatory uncertainty, cash runway assumptions, dependence on further financing and potential dilution, and the possibility that insufficient funding could delay, reduce, or halt development. The filing reports no material legal matters, no contingent liabilities, and no material changes to previously disclosed risk factors.
Most important facts for investors to verify
- Whether clinical studies for NXP800 and NXP900 meet enrollment, safety, and efficacy objectives, and whether planned studies proceed.
- Actual cash burn and the duration of runway as development spending rises; the 12-month estimate depends on assumptions that may prove incorrect.
- Future financing needs, ATM usage, share dilution, and the remaining availability of registered offering capacity.
- Timing and potential cost of license milestones, research commitments, and royalties if development or commercialization progresses.